| Date | Title | Description |
| 27.09.2024 | Vicebio's $100 Million Bet on Respiratory Virus Vaccines | In the bustling world of biopharmaceuticals, Vicebio has emerged as a player to watch. The London-based company recently secured $100 million in Series B financing. This funding is a lifeline, propelling Vicebio into the spotlight of vaccin... |
| 27.09.2024 | Vicebio: $100 Million (Series B) Raised To Develop Novel Vaccines Against Respiratory Viral Infections | Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, announced a $100 million Series B financing led by TCGX. Goldman Sachs Alternatives, Avoro Ventures, and venBio invested, ... |
| 23.09.2024 | Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1 | The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.
The British biotech has secured $100 million in series B funds as it continues a phase 1 trial of its biva... |
| 23.09.2024 | Vicebio Raises $100M in Series B Financing | Vicebio, a London, UK-based biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, raised $100M in Series B funding.
The round was led by TCGX with investment from Goldman Sachs Alternativ... |
| - | Vicebio | “Vicebio | A new generation of vaccines made for people” |